For these patients, oral B12 supplementation (1,000-2,000 mcg daily sublingual methylcobalamin) provides comparable B12 repletion without injection
Refine your workspace: Clean your hands and prep a sterile area before every injection
It's important to note that while AOD9604 shows promise, further large-scale human clinical trials are necessary to fully establish its efficacy and long-term safety profile
Disease preventing adequate oral nutrition: A medical condition (such as severe dysphagia, head and neck cancer, or neurological injury) makes oral feeding unsafe or impossible
Exercise programming: Resistance training 3-5x weekly to maintain muscle mass during fat loss, moderate-intensity cardiovascular activity to enhance fat oxidation, and potentially fasted morning cardio to leverage elevated free fatty acids from AOD-9604 administration
Safety across the full program was consistently favorable: adverse events, primarily mild headache and gastrointestinal symptoms, occurred at rates comparable to placebo, with no treatment-related discontinuations, no IGF-1 elevation, and no impact on glucose metabolism